Firefly Neuroscience 3Q 2026: Revenue $647K, EPS ($0.07) — 10-Q Summary

Firefly Neuroscience reported 3Q 2026 revenue of $647K, up 67% YoY, with net loss narrowing to $1.48M. Growth was driven by recurring subscription revenue, while gross margin improved to 81%. Operating expenses decreased, including selling and marketing costs down 27%. The Evoke EEG System is in use at 85+ U.S. clinical sites.

Original reporting
Published Nov 10, 2026, 11:11 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 11:15 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Firefly Neuroscience 3Q 2026: Revenue $647K, EPS ($0.07) — 10-Q Summary — source image
Decision brief

The 30-second read

$AIFFBullishMed
01

Why it matters

The earnings release provides fresh data on a micro‑cap biotech, offering a potential short‑term trade idea.

02

Market read

First‑time earnings disclosure for a micro‑cap; may trigger modest price movement.

03

What to watch

Cash burn and need for further financing could limit upside.

Relevance 7/10Novelty 7/10Timing: post‑market today

Background

Firefly Neuroscience filed its 10‑Q for Q3 2026, highlighting subscription‑driven revenue growth and cost reductions.

Company-level read

Ticker impact

$AIFFBullishMedium confidence
Context

Firefly Neuroscience reported Q3 2026 revenue of $647K, a 67% YoY increase, and a narrowed net loss.

Expected impact

likely modest upside as market prices in improved margins and lower expenses

Evidence & confidence

Revenue rose sharply and gross margin improved to 81%, indicating better operating leverage for a micro‑cap biotech.

Market effects

Shows strengthening demand for neuro‑diagnostic subscription services.

Limited to U.S. biotech investors.

Minimal beyond niche neuro‑tech segment.

Counterpoint

Despite revenue growth, the company remains loss‑making; investors may stay cautious.

Key entities

  • Firefly Neuroscience, Inc.

    Neuro‑diagnostic device and software provider.

Related articles

$AIFFHighAI 8/10

AI Stock Firefly Neuroscience (NASDAQ: AIFF) Soars on First FDA-Cleared, Non-Drug Treatment for Pediatric ADHD

Firefly Neuroscience (NASDAQ: AIFF) stock surged 32.77% after announcing a partnership with NeuroSigma to expand access to the FDA-cleared Monarch eTNS(R) System, a non-drug treatment for pediatric ADHD. The stock traded at $1.58 on high volume. Firefly's Evoke(TM) platform provides AI-powered brain function analytics to clinicians. According to a 2024 study, approximately 7.1 million U.S. children have been diagnosed with ADHD, with nearly one-third receiving no treatment.

$AIFFHigh

Firefly Hikes on Partnering with NeuroSigma

Firefly Neuroscience (AIFF) and NeuroSigma partnered to promote NeuroSigma's Monarch eTNS System, a non-drug ADHD treatment, through Firefly's Evoke platform network. AIFF shares rose 38.9% to $1.65. According to a 2024 study, 7.1 million U.S. children have ADHD, with many seeking non-medication treatments.

$CISSMedAI 8/10

C3is (CISS) Q3 2026 Earnings Call Transcript

C3is (CISS) reported Q3 2026 earnings, with voyage revenues up 249% YoY to $16.7M and nine-month revenues up 116% to $52.4M. Adjusted net income increased 1,300% YoY to $13.2M. Cash balance rose 335% to $64.9M. The company expanded its fleet and secured time charters for bulk carriers. Management highlighted strong market demand for iron ore, coal, and grain, driving shipping rates.

$NVDAHighAI 9/10

What's Going On With Nvidia Stock Wednesday

Nvidia (NVDA) reported quarterly earnings of $2.68 per share on revenue of $115.84 billion, beating estimates. Data center sales reached $107.6 billion. The company raised its revenue forecast for the current quarter and long-term growth outlook, but expects no revenue from China. Nvidia also expanded its stock buyback program.